Showing results (121-130 of 1,359) with videos related to
Sort By:
Pageof 136
Handbook of Experimental Pharmacology|November 8, 2019
Why Are New Drugs Expensive and How Can They Stay Affordable?Basma Hammel, Martin C MichelHandbook of Experimental Pharmacology|July 13, 2023
Sex and Gender Differences in the Pharmacology of the Overactive Urinary BladderAndrea Pautz, Martin C MichelExpert Opinion on Drug Safety|March 9, 2016
Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studiesMartin C Michel, Stavros GravasThe Journal of Physiology|June 15, 1997
Differing effects of histamine and serotonin on microvascular permeability in anaesthetized ratsC C Michel, S KendallExpert Opinion on Therapeutic Targets|February 24, 2015
Therapeutic targets for overactive bladder other than smooth muscleMartin C Michel, Yasuhiko IgawaEndocrinology|June 2, 1998
Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtypeA Bischoff, M C MichelHandbook of Experimental Pharmacology|September 13, 2025
Biased Agonism at β-Adrenoceptor Subtypes: A Drug Development PerspectiveMartin C Michel, Ongun OnaranCanadian Journal of Physiology and Pharmacology|March 29, 2000
Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretionA Bischoff, M C MichelPediatric Blood & Cancer|January 31, 2019
ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effectsErica Brivio, C Michel ZwaanEuropean Urology|December 9, 2000
Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practiceM C Michel, M GoepelPageof 136